Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07599176 · ClinicalTrials.gov registry record · Phase 1
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
A Phase 1 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07599176 is a Phase 1 study that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 90 participants.
The verdict
NCT07599176, a Phase 1 study, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cells to stably remain in the recipients long term.
Interventions
- DRUG Alemtuzumab
- DRUG Abatacept
- RADIATION Total Body Irradiation
- OTHER Research blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2035-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07599176
The ClinicalTrials.gov registry entry for NCT07599176 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Alemtuzumab is the first listed.
NCT07599176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07599176 about?
NCT07599176 is a clinical study titled "Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors". This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cells...
What is the current status of trial NCT07599176?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-07-15. Estimated completion is 2035-06-30.
What interventions are being tested in trial NCT07599176?
The interventions under investigation include: Alemtuzumab (DRUG), Abatacept (DRUG), Total Body Irradiation (RADIATION), Research blood draw (OTHER).
Who is sponsoring clinical trial NCT07599176?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.